Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinical management of hypophosphatemic osteomalacia induced by adefovir and tenofovir: Insights from a case report.
Medicine (Baltimore)
November 2024
Department of Endocrinology, Lishui Central Hospital, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang Province, China.
Article Synopsis
- Hypophosphatemic osteomalacia is a rare condition marked by low phosphate levels, which can occur due to genetic or acquired factors, and a case study discusses its management and prognosis when caused by specific antiviral drugs.
- A 55-year-old man with chronic hepatitis B experienced symptoms like chest pain and fatigue after switching from adefovir to tenofovir, leading to the diagnosis of drug-induced hypophosphatemic osteomalacia.
- Treatment included stopping the problematic drugs, switching to entecavir, and recommending dietary changes and supplements, which resulted in improved phosphate levels and resolution of symptoms.
Understanding adefovir pharmacokinetics as a component of a transporter phenotyping cocktail.
Eur J Clin Pharmacol
July 2024
Department I of Pharmacology, Center for Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Gleueler Straße 24, Cologne, 50931, Germany.
Article Synopsis
- Adefovir was studied to understand how it interacts with renal transporters when combined with other drugs, showing a 20% increase in systemic exposure when used together with metformin, sitagliptin, pitavastatin, and digoxin.
- A population pharmacokinetic (popPK) model was used to analyze data from 24 healthy subjects, revealing that adefovir's absorption and bioavailability were significantly higher during combination therapy compared to when it was administered alone.
- The findings indicate that while co-administering drugs mainly influenced adefovir's absorption and conversion, its renal elimination process remained unchanged, suggesting limited drug-drug interactions in this context.
Coxsackie B virus-induced myocarditis in a patient with a history of lymphoma: A case report and review of literature.
Medicine (Baltimore)
March 2024
Department of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Introduction: In rare occasions, coxsackievirus infections can cause serious illness, such as encephalitis and myocarditis. The immunotherapies of cancer could increase the risk of myocarditis, especially when applying immune checkpoint inhibitors. Herein, we report a rare case of Coxsackie B virus-induced myocarditis in a patient with a history of lymphoma.
View Article and Find Full Text PDFAre the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?
Clin Liver Dis
November 2023
Department Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea. Electronic address:
In treatment-naïve patients with chronic hepatitis B virus (HBV) infection, entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide have a minimal or no risk of drug-resistance. These 3 nucleos(t)ide analog agents are highly potent inducing high rate of virologic response (reducing serum HBV DNA to levels undetectable by polymerase chain reaction assays) in most treatment-naïve patients. Our randomized trials have demonstrated that monotherapy with TDF can provide a successful virological response in most of the heavily pretreated patients with multidrug resistance to ETV or adefovir.
View Article and Find Full Text PDFHigh Frequency of Antiviral Resistance Mutations in HBV Genotypes A2 and H: Multidrug Resistance Strains in Mexico.
J Clin Transl Hepatol
October 2023
Department of Genomic Medicine in Hepatology, Civil Hospital of Guadalajara, "Fray Antonio Alcalde," Guadalajara, Jalisco, Mexico.
Article Synopsis
- This study investigates the prevalence of antiviral resistance and escape mutations in hepatitis B virus (HBV) infections in Mexico, focusing on various antiviral drugs including Lamivudine and Tenofovir.
- In a sample of 158 patients, the most common HBV genotype found was H (68.4%), with a notable 8.2% prevalence of resistance mutations, primarily the combined mutation rt180M+rt204V.
- Results point to the highest prevalence of resistance and escape mutations in genotypes A2 and H, marking an early detection of multidrug resistance cases in the region.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!